Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial

Annals of Oncology ◽

10.1093/annonc/mdl079 ◽

2006 ◽

Vol 17 (6) ◽

pp. 957-961 ◽

Author(s):

J. Sehouli ◽

G. Oskay-Özcelik ◽

J. Kühne ◽

D. Stengel ◽

H.-J. Hindenburg ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Multicenter Phase

Download Full-text

Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2411-2 ◽

2014 ◽

Vol 73 (4) ◽

pp. 819-825 ◽

Author(s):

Filippos Koinis ◽

Aristidis Polyzos ◽

Athina Christopoulou ◽

Zafeiris Zafeiriou ◽

Christos Emmanouilidis ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Research Group ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Salvage Chemotherapy ◽

Oncology Research ◽

Multicenter Phase ◽

Pretreated Patients

Download Full-text

Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.5043 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 5043-5043 ◽

Author(s):

P. Chinet-Charrot ◽

F. Joly ◽

H. Bourgeois ◽

A. Lortholary ◽

B. Leduc ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Multicenter Phase

Download Full-text

Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, nonrandomized, multicenter, phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps254 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS254-TPS254 ◽

Author(s):

K. D. Steffensen ◽

M. Waldstr∅m ◽

B. Lund ◽

K. Bergfeldt ◽

N. Keldsen ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Wild Type ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.09.036 ◽

2010 ◽

Vol 116 (3) ◽

pp. 312-316 ◽

Author(s):

Florence Joly ◽

Emmanuel Sevin ◽

Alain Lortholary ◽

Frank Priou ◽

J.F. Paitel ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Multicenter Phase

Download Full-text

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-008-0306-9 ◽

2009 ◽

Vol 117 (3) ◽

pp. 591-598 ◽

Author(s):

Elmar Stickeler ◽

Maximilian Klar ◽

Dirk Watermann ◽

Annette Geibel ◽

Martha Földi ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin ◽

Multicenter Phase ◽

Download Full-text

Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum

Gynecologic Oncology ◽

10.1016/j.ygyno.2008.09.033 ◽

2009 ◽

Vol 112 (1) ◽

pp. 35-39 ◽

Author(s):

Sheng-Mou Hsiao ◽

Chi-An Chen ◽

Ho-Hsiung Lin ◽

Chang-Yao Hsieh ◽

Lin-Hung Wei

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Sensitive ◽

Download Full-text

Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5072 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5072-5072 ◽

Author(s):

J. Sehouli ◽

G. Oskay ◽

I. Katsares ◽

P. Klare ◽

H. J. Hindenburg ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): Survival results of a GINECO phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.5022 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5022-5022 ◽

Author(s):

J.-M. Ferrero ◽

B. Weber ◽

D. Lepille ◽

H. Orfeuvre ◽

M. Combe ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin

Download Full-text

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5045 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5045-5045 ◽

Author(s):

R. W. Naumann ◽

R. L. Coleman ◽

R. A. Burger ◽

T. J. Herzog ◽

R. Morris ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text